These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32409306)

  • 1. Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research.
    Chargari C; Levy A; Paoletti X; Soria JC; Massard C; Weichselbaum RR; Deutsch E
    Clin Cancer Res; 2020 Sep; 26(18):4723-4736. PubMed ID: 32409306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug radiotherapy combinations: review of previous failures and reasons for future optimism.
    Higgins GS; O'Cathail SM; Muschel RJ; McKenna WG
    Cancer Treat Rev; 2015 Feb; 41(2):105-13. PubMed ID: 25579753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report.
    Thomas G; Eisenhauer E; Bristow RG; Grau C; Hurkmans C; Ost P; Guckenberger M; Deutsch E; Lacombe D; Weber DC;
    Eur J Cancer; 2020 May; 131():76-88. PubMed ID: 32305726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.
    Searle EJ; Illidge TM; Stratford IJ
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):266-76. PubMed ID: 24602563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Cancer Literature Reflect Multidisciplinary Practice? A Systematic Review of Oncology Studies in the Medical Literature Over a 20-Year Period.
    Holliday EB; Ahmed AA; Yoo SK; Jagsi R; Hoffman KE
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):721-31. PubMed ID: 26104927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Damage Repair Deficiency in Prostate Cancer.
    Burdak-Rothkamm S; Mansour WY; Rothkamm K
    Trends Cancer; 2020 Nov; 6(11):974-984. PubMed ID: 32517958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.
    Bristow RG; Alexander B; Baumann M; Bratman SV; Brown JM; Camphausen K; Choyke P; Citrin D; Contessa JN; Dicker A; Kirsch DG; Krause M; Le QT; Milosevic M; Morris ZS; Sarkaria JN; Sondel PM; Tran PT; Wilson GD; Willers H; Wong RKS; Harari PM
    Lancet Oncol; 2018 May; 19(5):e240-e251. PubMed ID: 29726389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives.
    Antoni D; Mornex F
    Curr Opin Oncol; 2016 Mar; 28(2):104-9. PubMed ID: 26848885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocoxin as a complement to first line treatments in cancer.
    Benedicto A; Sanz E; Márquez J
    Int J Med Sci; 2021; 18(3):835-845. PubMed ID: 33437220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the efficacy of chemoradiation with targeted agents.
    Morgan MA; Parsels LA; Maybaum J; Lawrence TS
    Cancer Discov; 2014 Mar; 4(3):280-91. PubMed ID: 24550033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.
    Hafez N; Rugo HS; Tempero MA; Fox E; Reaman GH; Lyerly HK; Walker D; LoRusso PM
    Clin Cancer Res; 2020 Sep; 26(18):4743-4747. PubMed ID: 32571790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy for Non-Hodgkin Lymphomas.
    Imber BS; Yahalom J
    Cancer J; 2020; 26(3):217-230. PubMed ID: 32496455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of chemotherapy and radiotherapy: A thirty years evolution.
    Hennequin C; Guillerm S; Quero L
    Cancer Radiother; 2019 Oct; 23(6-7):662-665. PubMed ID: 31473087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Insights in Radiation Combination Therapies: Influence of Omics and Novel Targeted Agents in Defining New Concepts in Radiation Biology and Clinical Radiation Oncology.
    Ahmed MM; Narendra A; Prasanna P; Coleman CN; Krishnan S
    Semin Radiat Oncol; 2016 Oct; 26(4):251-3. PubMed ID: 27619246
    [No Abstract]   [Full Text] [Related]  

  • 16. The Role of Radiation Oncology in Immuno-Oncology.
    Meng X; Feng R; Yang L; Xing L; Yu J
    Oncologist; 2019 Feb; 24(Suppl 1):S42-S52. PubMed ID: 30819830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
    Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
    Front Immunol; 2018; 9():3107. PubMed ID: 30692993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].
    Ghiringhelli F
    Biol Aujourdhui; 2018; 212(3-4):77-79. PubMed ID: 30973135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.
    Cushman TR; Caetano MS; Welsh JW; Verma V
    Immunotherapy; 2018 Aug; 10(10):851-0. PubMed ID: 30073899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current clinical management of patients with glioblastoma.
    Lowe S; Bhat KP; Olar A
    Cancer Rep (Hoboken); 2019 Dec; 2(6):e1216. PubMed ID: 32721125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.